Ann: Kazia's paxalisib obtains Rare Pediatric Disease Designation, page-101

this is right and given the company themselves mentioned the latest raise takes us through that trial to marketing and Edison's a favourite of some/one poster notes that we are saving approx 50% on trial costs meaning we are buying a 40 mill trial for our 20 mill - saving yet tens of millions in the process

it it should be noted GBM Agile has already treated hundreds on the first compound of this game changing multiarm study - they are moving super fast! And so will we as we are beginning to open this next exciting phase.

wilful ignorance by a known party who by their own confession could not hold their shares long enough to sit on the massive gains many here now are is testament to the old investing adage 'money moves from the impatient to the patient'

as james mentioned in a recent investor webinar this may be the last raise we perform and we are well funded adding the recent raise to already enough money to take us well into next year - the timing was based on external market conditions.

more data coming this year will change the landscape after years of setup and the recent 100% gains over the last couple months are just the foothills for SP growth - many coming data readouts across a swag of trials

exciting times ahead,